Infectious Disease Diagnostics Market

Loading

Loading.

Loading..

Loading...

SPER Market Research


Infectious Disease Diagnostics Market

Share

Infectious Disease Diagnostics Market

 Category : Medical Devices

 Published: Aug-2021
 Author: SPER Analyst
Infectious Disease Diagnostics Market is projected to be worth around USD 41.6 Billion by 2027

The global infectious disease diagnostics market is expected to grow at a CAGR of 7.9% from 2020 to reach 41.6 billion by 2027. The growth in the infectious disease diagnostics market is mainly attributed to prevalence of infectious diseases, technological advancements, global outbreak of COVID-19 and shift of demand from centralized laboratories to various decentralized diagnostic POC kits. However, unfavourable and inadequate reimbursement scenarios can pose significant challenge.

Browse report overview on "Infectious Disease Diagnostics Market" at: https://www.sperresearch.com/report-store/Infectious-Disease-Diagnostics.aspx

The global infectious disease diagnostics market study provides market data for-by product (Reagents, kits and consumables, Instruments and software & services), by type of testing (Laboratory testing and POC testing), by technology (Immunodiagnostics, clinical microbiology, PCR, INAAT, DNA Sequencing & NGS, DNA Microarrays and other technologies), by disease type (COVID-19, HIV, HAIs, Hepatitis, CT/NG, HPV, TB, Influenza and other Infectious Diseases), by End User (Diagnostic Laboratories, Hospitals & Clinics, Academic Research Institutes and other End Users). The study also evaluates industry competitors and analyses the market at a regional and country level.

By product, reagents, kits and consumables segment accounted for the largest market share in 2020. The growth of this market is driven by frequent purchase of these products for recurrent usage.

POC testing segment is expected to register highest CAGR of infectious disease diagnostics market by type of testing. This growth can be ascribed by need to closely monitor patients and faster rate of diagnosis.

Immunodiagnostics segment accounted for the largest market share by technology in 2020. The growth of this segment was driven by increased immunoassays for COVID-19 testing, increased POC infectious disease testing, development of novel diagnostic test kits and rising automation trend. 

Hepatitis segment accounted for largest share of infectious disease diagnostics market in 2020 by disease. The growth was driven by prevalence of hepatitis B & C, increasing blood transfusions, increasing geriatric population and benefits offered by POC kits and instruments. 

Don’t miss out on business opportunities in the global infectious disease diagnostics market. Request customized report as per your need and gain crucial industry insights that will help your business grow at: https://www.sperresearch.com/report-store/Infectious-Disease-Diagnostics.aspx?cutom=1

On the basis of End user, Diagnostic laboratories segment is expected to register largest share of infectious disease diagnostics market. The growth can be accounted to factors such as prevalence of infectious diseases and strengthening of healthcare infrastructure.

This research report analyses major geographies and provides a comprehensive analysis of North America (US, Canada), Europe (Germany, France, UK, Italy, Spain and Rest of Europe), Asia-Pacific (China, India, Japan, and RoAPAC), Rest of the world (Latin America, and Middle East & Africa). North America accounted for the largest regional market share of infectious disease diagnostics. The growth was mainly attributed to technological advancement, presence of clinical laboratories with easy access and developed healthcare infrastructure. However, Asia-pacific is the fastest growing regional market due to rapid urbanization, government initiatives, increased investments on healthcare system and improved accessibility to diagnostic services.

The major players operating in the global infectious disease diagnostics market are 
  • Abbott Laboratories (US)
  • F. Hoffmann-La Roche Ltd(Switzerland)
  • bioMérieux SA (France)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)
  • Quidel Corporation (US)
  • Hologic, Inc. (US)
  • Siemens Healthineers AG (Germany)
  • Becton Dickinson and Company (US)
  • PerkinElmer Inc. (US)
  • QIAGEN (Netherlands)
  • Grifols S.A. (Spain)
  • DiaSorin S.p.A (Italy)
  • Bio-Rad Laboratories, Inc. (US)
  • Sysmex Corporation (Japan)
  • Ortho Clinical Diagnostics (US)
  • Luminex Corporation (US)
  • Meridian Bioscience (US)
  • Genetic Signatures (Australia)
  • OraSure Technologies (US)
  • Trinity Biotech Plc. (Ireland)
  • Chembio Diagnostic Systems, Inc. (US)
  • Seegene Inc. (South Korea)
  • Co-Diagnostics, Inc. (US)
  • ELITechGroup (France)
  • Epitope Diagnostics, Inc. (US)
  • Trivitron Healthcare (India)
  • Meril Life Sciences Pvt. Ltd. (India)
  • InBios International, Inc. (US)
  • and ABACUS Diagnostica Oy (Finland)

Join SPER Panel

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Secure Payments
SPER Payment Options
Connect with us